BGM
BBIO icon

Burkehill Global Management’s BridgeBio Pharma BBIO Stock Holding History

Burkehill Global Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-275,000
Closed -$14.3M – 161
2025
Q3 		$14.3M Hold
275,000
– – 0.81% 39
2025
Q2 		$11.9M Buy
+275,000
New +$10M 0.88% 35

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Burkehill Global Management's BBIO Position: Q4 2025 in Review

Burkehill Global Management sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 275,000 shares — an estimated $14.3M sold.

Burkehill Global Management first reported a position in BBIO in Q2 2025 and held it in 2 quarters. The position peaked at $14.3M in Q3 2025. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Burkehill Global Management reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Burkehill Global Management sold 275,000 BridgeBio Pharma shares in Q4 2025, an estimated $14.3M.
  • Burkehill Global Management first reported a position in BridgeBio Pharma in Q2 2025 and held it in 2 quarters.
  • Burkehill Global Management's BridgeBio Pharma position peaked at $14.3M in Q3 2025.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Burkehill Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.